Back to Results

A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Sarah Davis,  MD

Sarah Davis, MD

Study ID

Protocol Number: 19-1503

More information available at ClinicalTrials.gov: NCT04003636

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers